Head-to-head comparison
| Property | Gramicidin | Polymyxin B |
|---|---|---|
| Category | Other | Other |
| Legal Status | Prescription | Prescription |
| Primary Route | topical | topical |
| Half-life | not applicable (topical use; retained at application site) | ~6 hours (IV, varies with renal function) |
| Mol. Weight | 1,882.28 Da | 1,301.56 Da |
| Side Effects | Local eye irritation, Allergic contact dermatitis, Hemolytic if absorbed systemically (limits systemic use) | Nephrotoxicity (30–60% with systemic use), Neurotoxicity (paresthesias, dizziness, ataxia), Injection site pain (IM) |
Key differences
- Source: Gramicidin is produced by Bacillus brevis; polymyxin B is produced by Paenibacillus polymyxa (formerly Bacillus polymyxa). Both were isolated in the 1940s, near the dawn of the antibiotic era.
- Mechanism: Gramicidin forms cation-selective transmembrane channels that collapse the bacterial electrochemical gradient; polymyxin B binds lipid A of lipopolysaccharide (LPS) in the gram-negative outer membrane, displacing stabilizing divalent cations and disrupting membrane integrity.
- Spectrum: Gramicidin is narrow-spectrum and primarily active against gram-positive organisms; polymyxin B is narrow-spectrum but targets gram-negative organisms, including the most clinically significant MDR pathogens (CRAB, CRE, MDR P. aeruginosa).
- Route and indication: Gramicidin is FDA-approved only for topical ophthalmic use (Neosporin Ophthalmic Solution, with neomycin and polymyxin B); polymyxin B is FDA-approved for both topical and systemic (IV/IM) use, with systemic use reserved for life-threatening MDR gram-negative infections.
- Toxicity profile: Gramicidin causes rapid hemolysis at any systemically relevant concentration, which is why it has never been developed as a systemic antibiotic; polymyxin B causes nephrotoxicity in 30-60% of systemically treated patients and dose-limiting neurotoxicity (paresthesias, dizziness) at higher exposures.
- Resistance: Gramicidin resistance is rare due to its membrane-level mechanism; polymyxin B resistance has emerged via the plasmid-borne MCR-1 gene (first described 2015) and chromosomal pmrA/pmrB mutations, with global surveillance tracking spread in food-animal and clinical isolates.
- Commercial overlap: Both appear in Neosporin Ophthalmic Solution alongside neomycin — the only widely marketed triple-antibiotic ophthalmic preparation that pairs two peptide antibiotics (gramicidin + polymyxin B) with an aminoglycoside (neomycin).
The verdict
Gramicidin and polymyxin B are complementary, not competing, antibiotics. Gramicidin occupies a narrow but stable niche in topical ophthalmic practice, where its gram-positive spectrum covers the staphylococcal and streptococcal organisms that dominate conjunctivitis; polymyxin B occupies the far more consequential niche of last-resort systemic therapy for multidrug-resistant gram-negative infections, a role that has grown in importance as carbapenem resistance has spread globally. Neither has a viable development path outside its current niche — gramicidin's hemolysis precludes systemic use, and polymyxin B's nephrotoxicity precludes routine first-line use. Their co-formulation in Neosporin Ophthalmic represents a rational spectrum-coverage strategy (gram-positive + gram-negative + aminoglycoside-susceptible organisms) in an environment (the eye) where systemic toxicity is minimal.
Frequently asked questions
Neosporin Ophthalmic combines three antibiotics with complementary spectra: gramicidin covers gram-positive organisms, polymyxin B covers gram-negative organisms, and neomycin (an aminoglycoside) covers additional gram-negative and some gram-positive organisms. The combination is designed to provide broad empiric coverage for bacterial conjunctivitis before culture results are available. Neither peptide antibiotic is used systemically in this formulation because the ophthalmic route minimizes systemic absorption.
Yes, in the systemic-use context. Polymyxin B and its close relative colistin (polymyxin E) are reserved for infections caused by carbapenem-resistant Enterobacteriaceae (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), and multidrug-resistant Pseudomonas aeruginosa — pathogens for which few alternatives exist. The nephrotoxicity rate (30-60%) and neurotoxicity risk make these drugs undesirable for routine use, but the emergence of pan-resistant organisms has forced clinicians to return to them.
Gramicidin's cation-channel mechanism is not selective for bacterial versus mammalian cell membranes at systemic concentrations. Injected gramicidin causes rapid hemolysis — destruction of red blood cells — at doses far below the threshold needed for antimicrobial effect in vivo. Topical application to mucosal surfaces like the conjunctiva produces negligible systemic absorption, which is why topical use has been FDA-approved since the 1940s while systemic use has never been viable.
MCR-1 is a plasmid-borne gene first identified in China in 2015 that confers polymyxin resistance by modifying the lipid A target. Unlike chromosomal polymyxin resistance (which is rare and hard to transmit), MCR-1 is transferable between bacterial species via horizontal gene transfer, raising the specter of pan-resistant gram-negative pathogens. Surveillance programs now track MCR-1 globally in food-animal and clinical isolates, and its spread has accelerated the search for new gram-negative agents.
Both are peptide antibiotics. Gramicidin is a linear pentadecapeptide (15 amino acids) with alternating L- and D-isomers; polymyxin B is a cyclic decapeptide with a lipopeptide tail (fatty acid attached to a cyclic peptide ring). Both predate the classification 'peptide antibiotic' as a category, which is why they are sometimes grouped with conventional antibiotics for clinical purposes. Structurally and mechanistically, they belong firmly in the peptide-antibiotic class.
Several newer agents have emerged since 2015: ceftazidime-avibactam, meropenem-vaborbactam, ceftolozane-tazobactam, and cefiderocol each target different resistance mechanisms. However, none fully replaces polymyxin B — each has gaps in coverage (for example, cefiderocol has emerging resistance concerns with some CRAB strains). Polymyxin B remains important for organisms that outrun the newer agents, particularly pan-resistant Acinetobacter baumannii.